ClinicalTrials.gg
Active, not recruitingNCT07456839Updated May 26, 2026

A Mutiple-dose Study of IBI3033 in Healthy Participants

A Phase 1 interventional study of Placebo and IBI3033 in Healthy Participants, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 8-week treatment period and 8-week follow-up period.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males/females aged 18-55 years (inclusive).
  2. 18.0-28.0 kg/m²; weight ≥50 kg (male) or ≥45 kg (female).
  3. Willing to use effective for 6 months post-dosing.

Exclusion criteria

Exclusion Criteria:

  1. History of blood or needle sickness, or those who cannot tolerate venipuncture.
  2. Female participants who are pregnant or breastfeeding at screening or randomization.
  3. History of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening.
  4. History of live or attenuated vaccination within 1 month prior to screening, or those who plan to be vaccinated during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Placebo comparator
    Placebo SC

    Participants in placebo group will receive placebo SC.

    Drug: Placebo

  • Experimental
    IBI3033 Dose 2 SC

    Participants in IBI3033 group will receive multiple doses of IBI3033 SC at the protocol specified dose level and time points.

    Drug: IBI3033

  • Experimental
    IBI3033 Dose 1 subcutaneously (SC)

    Participants in IBI3033 group will receive multiple doses of IBI3033 SC at the protocol specified dose level and time points.

    Drug: IBI3033

Interventions

  • DrugPlacebo

    Participants in placebo group will receive placebo SC.

  • Participants in IBI3033 group will receive multiple doses of IBI3033 SC at the protocol specified dose level and time points.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)/serious adverse events (SAEs)

    Percentage of participants who have experienced AEs/SAEs

    Time frame: Baseline to Day 113

Secondary outcomes

  1. PK parameter: Cmax

    Observed maximum plasma concentration of IBI3033

    Time frame: Baseline to Day 113

  2. PK parameter: tmax

    Time to achieve Cmax of IBI3033

    Time frame: Baseline to Day 113

  3. PK parameter: AUC

    Area under the plasma concentration-time curve of IBI3033

    Time frame: Baseline to Day 113

  4. Immunogenticity profiles

    Frequency of anti-drug antibody (ADA) of IBI3033

    Time frame: Baseline to Day 113

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 9, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Nov 13, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07456839
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 18, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Nov 13, 2026 (estimated)
Last update
May 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3033

Start the discussion